Arca Biopharma Up On Completing Patient Enrollment In Covid: 19 study

Oruka Therapeutics

02/12/2021 13:50

** Drug developer's shares  ABIO.O  rise 3.1% to $2.34
premarket
    ** Co completes patient enrollment in mid-stage trial
testing rNAPc2 as a potential treatment for patients
hospitalized with COVID-19 (https://refini.tv/3DibkOK)
    ** 160 patients enrolled at clinical sites in U.S.,
Argentina and Brazil
    ** Co anticipates reporting topline data from trial in Q1 of
2022
    ** Up to Wednesday's close, stock had fallen 43.4% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))